Can AbelZeta turn a tiny lupus dataset into a registrational CAR-T breakthrough?
AbelZeta's FDA-cleared Phase II C-CAR168 trial tests whether dual-target CAR-T can deliver durable renal responses in refractory lupus nephritis.
Pharma & Biotech
Pharma & Biotech
Why Aurinia’s new Lupkynis trial could change the lupus nephritis treatment sequence
Discover how Aurinia’s PRESERVE study could reshape lupus nephritis care by combining Lupkynis with three major biologic therapies.
Pharma & Biotech
FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment
FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.
Pharma & Biotech
Could Hinge Bio, Inc. unlock a new class of lupus B-cell depletion therapies?
Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.
Pharma & Biotech
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.